Status:
RECRUITING
Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
Lead Sponsor:
University of Iowa
Conditions:
Electronic Cigarette Use
Endothelial Dysfunction
Eligibility:
All Genders
18-24 years
Phase:
EARLY_PHASE1
Brief Summary
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in ...
Eligibility Criteria
Inclusion
- 18 - 24 years of age
- no history of e-cigarette use (control) OR current with 6 months or more history of e-cigarette use (chronic use).
Exclusion
- tobacco cigarette use (current or history of)
- use of stimulant drugs
- skin diseases
- cardiovascular disease
- diagnosed or suspected hepatic or metabolic disease including diabetes
- statin or other cholesterol-lowering medication
- antihypertensive medication
- current pregnancy or breastfeeding
- blood pressure greater than or equal to 140mmHg systolic and/or greater than or equal to 90mmHg diastolic
- allergy to materials used during the experiment
- known allergies to salsalate or other study drugs
Key Trial Info
Start Date :
August 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06489249
Start Date
August 15 2024
End Date
October 1 2026
Last Update
December 15 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Iowa Bioscience Innovation Facility
Iowa City, Iowa, United States, 52242
2
University of Iowa
Iowa City, Iowa, United States, 52242